reports
- Arancha Pineiro
- Christophe-Raphaël Ganet
- Martin Marandon-Carlhian
- Stephane Houri
- Thomas Zlowodzki
PUB PUBLICIS GROUPE SA
EQNR EQUINOR ASA
SOP SOPRA STERIA GROUP SA
KPN ROYAL KPN NV
DBK DEUTSCHE BANK AG
ACN ACCENTURE PLC CLASS A
NOVN NOVARTIS AG
FORTUM FORTUM OYJ
INF INFOTEL SA
SRT3 SARTORIUS AG PREF
ASY ASSYSTEM SA
OMV OMV AG
AMUN AMUNDI SA
SWP SWORD GROUP SE
AUB AUBAY SA
DSV DSV PANALPINA A/S
ATE ALTEN SA
CARL B CARLSBERG A/S CLASS B
CAP CAPGEMINI SE
SPL SANTANDER BANK POLSKA SA
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
HM B H&M HENNES & MAURITZ AB CLASS B
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
DIM SARTORIUS STEDIM BIOTECH SA
ALSN ALSO HOLDING AG
SNP PETROM S.A.
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
NA9 NAGARRO
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
GSK GSK PLC
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
NOVO B NOVO NORDISK A/S
ATO ATOS SE
MICC MAGNUM ICE CREAM COMPANY N.V. (THE)
- Christophe-Raphaël Ganet
- Martin Marandon-Carlhian
- Stephane Houri
- Thomas Zlowodzki
PUB PUBLICIS GROUPE SA
EQNR EQUINOR ASA
SOP SOPRA STERIA GROUP SA
KPN ROYAL KPN NV
DBK DEUTSCHE BANK AG
ACN ACCENTURE PLC CLASS A
NOVN NOVARTIS AG
FORTUM FORTUM OYJ
INF INFOTEL SA
SRT3 SARTORIUS AG PREF
ASY ASSYSTEM SA
OMV OMV AG
AMUN AMUNDI SA
SWP SWORD GROUP SE
AUB AUBAY SA
DSV DSV PANALPINA A/S
ATE ALTEN SA
CARL B CARLSBERG A/S CLASS B
CAP CAPGEMINI SE
SPL SANTANDER BANK POLSKA SA
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
HM B H&M HENNES & MAURITZ AB CLASS B
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
DIM SARTORIUS STEDIM BIOTECH SA
ALSN ALSO HOLDING AG
SNP PETROM S.A.
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
NA9 NAGARRO
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
GSK GSK PLC
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
NOVO B NOVO NORDISK A/S
ATO ATOS SE
MICC MAGNUM ICE CREAM COMPANY N.V. (THE)
Publicis Advances Working With Cancer with initiative to support 40 mi...
Publicis Advances Working With Cancer with initiative to support 40 million workers worldwide Publicis Advances Working With Cancer with initiative to support 40 million workers worldwide. New research reinforces the link between work and recovery, inspiring WWC’s AI Coach for employees with cancer & a renewed call to action for business leaders. February 4, 2026 - Paris - Following new research from Memorial Sloan Kettering Cancer Center and the Mayo Clinic, Publicis Groupe [Euronext Paris FR0000130577, CAC 40] today announces the latest advancement in Working with Cancer’s mission to ...
Publicis étend Working With Cancer avec une initiative visant à souten...
Publicis étend Working With Cancer avec une initiative visant à soutenir 40 millions de collaborateurs dans le monde Publicis étend Working With Cancer avec une initiative visant à soutenir 40 millions de collaborateurs dans le monde De nouvelles recherches réaffirmant l’importance du travail dans la rémission des patients ont conduit Working With Cancer à développer une solution d’IA dédiée à l’accompagnement des employés atteints de cancer et à renouveler son appel à l’engagement auprès des dirigeants d’entreprises. Paris, le 4 février 2026 – S’appuyant sur une nouvelle étude du Memo...
- Jerôme Bodin
- Jerôme Bodin
Intesa Sanpaolo S.p.A.: 1 director
A director at Intesa Sanpaolo S.p.A. sold 6,500 shares at 5.949EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
- Carole Braudeau
- Oliver Metzger
ETL EUTELSAT COMMUNICATIONS SA
SESGL SES SA FDR (CLASS A)
BVI BUREAU VERITAS SA
BN DANONE SA
BAER JULIUS BAER GRUPPE AG
FORTUM FORTUM OYJ
SRT3 SARTORIUS AG PREF
DEMANT DEMANT A/S
ITRK INTERTEK GROUP PLC
PKN POLSKI KONCERN NAFTOWY ORLEN S.A.
DIM SARTORIUS STEDIM BIOTECH SA
AKZA AKZO NOBEL N.V.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
SHEL SHELL PLC
SGSN SGS SA
- Oliver Metzger
ETL EUTELSAT COMMUNICATIONS SA
SESGL SES SA FDR (CLASS A)
BVI BUREAU VERITAS SA
BN DANONE SA
BAER JULIUS BAER GRUPPE AG
FORTUM FORTUM OYJ
SRT3 SARTORIUS AG PREF
DEMANT DEMANT A/S
ITRK INTERTEK GROUP PLC
PKN POLSKI KONCERN NAFTOWY ORLEN S.A.
DIM SARTORIUS STEDIM BIOTECH SA
AKZA AKZO NOBEL N.V.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
SHEL SHELL PLC
SGSN SGS SA
- Carole Braudeau
- Jerôme Bodin
- Pierre Tegner
- Jerôme Bodin
- Pierre Tegner
- Research Department
INFORME DIARIO 03 FEBRERO + RDOS. ESPAÑA Y EUROPA 4T’25. PREVIEWS (ANÁ...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: AEDAS HOMES, INDRA, MELIÁ, TELEFÓNICA, UNICAJA. EUROPA: INTESA SANPAOLO, UNICREDIT. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. El Ibex alcanza los 18.000 puntos Jornada de menos a más en las bolsas europeas, con el Ibex liderando de nuevo...
Publics Groupe: Full Year 2025 Results
Publics Groupe: Full Year 2025 Results N Very strong Q4 2025 at +5.9% Confident in delivering a 7th year of outperformance in 2026 February 3, 2026 +5.9% Q4 organic growth, leading to +5.6% in 2025Solid FY performance across all regions: U.S. at +5.2%, Europe +4.2% and APAC at +5.8%Industry-leading financial KPIs: 18.2% operating margin rate, up 20 basis points year-on-yearHeadline EPS of €7.48, up 6.6% at constant currencyFree cash flow1 at €2.0 billion, up 10.6%2025 proposed dividend at €3.75 per share, up 4.2%, fully paid in cash Expect to outperform again for 7th consecutive year in...
Publicis Groupe : Résultats annuels 2025
Publicis Groupe : Résultats annuels 2025 Un très bon T4 2025 à +5,9 % Confiants de surperformer une 7ème année consécutive en 2026 3 février 2026 +5,9 % de croissance organique au T4, soit +5,6 % sur l’année 2025Performance annuelle solide dans l’ensemble des régions : États-Unis à +5,2 %, Europe à+4,2 % et APAC à +5,8 % Indicateurs financiers les plus élevés de l’industrie : Taux de marge opérationnelle de 18,2 %, en amélioration de 20 points de base par rapport à 2024Bénéfice net courant par action de 7,48 €, en hausse de 6,6 % à taux de change constantFree cash flow1 de 2,0 Md€, en au...
- Javier Esteban
INTESA SANPAOLO: RDOS. 4T’25 (ANÁLISIS BANCO SABADELL)
Rdos. 4T'25 vs 4T'24: M. Intereses: 3.684 M euros (-3,1% vs -0,9% BS(e) y -2,3% consenso); M. Bruto: 6.838 M euros (+2,5% vs +1,6% BS(e) y +1,4% consenso); M. Explotación: 3.294 M euros (+6,8% vs +5,5% BS(e) y +5,4% consenso); BDI: 1.732 M euros (+15,5% vs +8,3% BS(e) y +6,1% consenso). Rdos. 4T'25 vs 3T'25: M. Intereses: 3.684 M euros (+0,1% vs +2,3% BS(e) y +1% consenso); M. Bruto: 6.838 M euros (+2,9% vs +2% BS(e) y +1,8% consenso); M. Explotación: 3.294 M euros (-16,2% vs -17,2 BS(e) y -18% ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.